Report ID: 10352475 |
Published Date: 21 Mar 2025 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
Global Pruritus Therapeutics Market Scope Report
|
Base Year |
2022 |
|
Forecast Year |
2023-2033 |
|
CAGR |
~4% |
|
Base Year Market Size (2022) |
~ USD 8 Billion |
|
Forecast Year Market Size (2033) |
~ USD 11 Billion |
Global Pruritus Therapeutics Market Size, Forecast, and Trend Highlights Over 2023 - 2033
The global pruritus therapeutics market is estimated to garner a revenue of ~ USD 11 billion by the end of 2033 by growing at a CAGR of ~4% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of ~ USD 8 billion in the year 2022. Pruritus, or itchy skin, is a sensation of skin irritation which is uncomfortable enough to make one want to scratch. The wide prevalence of skin diseases is the primary factor driving the growth of the global pruritus therapeutics market. Diseases that directly affect the skin are thought to affect about 2 billion people worldwide at any given time.
GET A SAMPLE COPY OF THIS REPORT
Skin conditions could be caused by many factors, including irritants, allergies, immune system problems, certain diseases, and genetic makeup. Pruritus is commonly associated with skin disorders, including atopic dermatitis, xerosis, urticaria, drug eruption, psoriasis, and dermatitis herpetiformis. A multi faced approach with medical therapy, elimination of aggravating factors, and treatment of underlying conditions comprises the treatment for pruritus.
Global Pruritus Therapeutics Market: Growth Drivers and Challenges
Growth Drivers
-
Common Occurrence with an Underlying Cause – It was observed that in up to 51% of patients who take treatment for pruritus, there were diagnoses of an underlying systemic disease. For instance, itching on the whole body is often reported as a symptom in patients with various illnesses, including kidney disease, anemia, liver disease, thyroid problems, diabetes, lymphoma, or multiple myeloma. Some pruritic conditions are iatrogenic in nature. A significant occurrence of pruritus in palliative medicine is opioid-induced pruritus.
-
Prevalence of Xerosis in Geriatric Population – It is estimated that xerosis, a condition associated with pruritus, should be observable in about 29- 76% of elderly population.
-
Use of Topical Corticosteroids for Treatment – About 27% of patients with pruritus who are treated with topical corticosteroids have been observed to react positively to the medication.
-
Common Occurrence of Urticaria in COVID-19 Patients – Urticaria was observed to affect about 2% of patients with severe COVID-19, while it affected ~1% of patients with mild symptoms.
Challenges
-
Side Effects of Medication and Therapies for Pruritus
-
Availability of Better Alternative Methods of Treatment for Pruritus
-
Difficulties in Determining the Cause of the Disease
The global pruritus therapeutics market is segmented and analyzed for demand and supply by drug type into corticosteroids, antihistamines, local anesthetics, immunosuppressants, and others. Of these, the corticosteroids segment is anticipated to hold the largest market size by the end of 2033. The wide, and varied use of the medicine for the treatment of many health conditions including, asthma, hay fever, and allergic rhinitis, is the reason for the segmental growth. For instance, fluticasone and prednisone are the two mostly prescribed corticosteroids, constituting ~22% and ~17% of the overall usage of corticosteroids. The high prevalence of skin-related conditions and the need for therapeutics are the other factors driving segmental market growth
Global Pruritus Therapeutics Market Regional Synopsis
Regionally, the global pruritus therapeutics market is studied into five major regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. Amongst these markets, the market in the North American region is projected to hold the largest market share by the end of 2033. The developed and specialized infrastructure in healthcare, favorable government initiatives, and a rise in the number of cases of skin diseases and other conditions are some factors affecting the regional market growth. For instance, there are over 5200 dermatologists’ businesses in only the United States (U.S.) as of 2022.
Market Segmentation
Our in-depth analysis of the global pruritus therapeutics market includes the following segments:
|
By Drug type |
|
|
By Disease Type |
|
|
By Distribution Channel |
|
Key Companies Dominating the Global Pruritus Therapeutics Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global pruritus therapeutics market that are included in our report are AbbVie Inc., Amgen Inc., Bausch Health Companies Inc., Cara Therapeutics, Inc., Cipla Inc., Eli Lilly and Company, Evelo Biosciences, Inc., Galderma SA, LEO Pharma A/S, Novartis AG, and others.
Global Pruritus Therapeutics Market: Latest Developments
-
September, 2022: Cara Therapeutics, Inc. announced the submission of a New Drug Application (NDA) in Japan by its licensing partner Maruishi Pharmaceutical Co., Ltd. The drug, difelikefalin is to be applied in the treatment of pruritus in hemodialysis patients.
-
June, 2022: Galderma SA announced the success of nemolizumab in the phase III OLYMPIA 2 trial in treating skin lesions and pruritus in adults suffering from moderate to severe prurigo nodularis.
Key Reasons to Buy Our Report
-
The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
Frequently Asked Question
The market is segmented by drug type, disease type, distribution channel, and by region.
The corticosteroids segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Why Choose Kenneth Research ?
-
Insight with Impact : We don’t just gather data — we uncover stories, trends, and opportunities that fuel business growth.
-
Experts Who Get It : Our team speaks your industry’s language and knows what really matters to your customers and market.
-
Custom-Built for You : Forget one-size-fits-all. We craft research and consulting solutions as unique as your business vision.
-
Partners, Not Just Providers : We work with you, not for you — collaborating closely to turn insights into smart, strategic moves.
-
Results That Speak : Our work powers brands, startups, and industry leaders alike — with a track record of ideas that work in the real world.
Report ID: 10352475 |
Published Date: 21 Mar 2025 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
